Durable clearance of hepatitis B virus after allogeneic blood stem cell transplantation by adoptive immunity transfer and antiviral chemotherapy

Medicine and Dentistry

• Stem Cell Therapy 100%
• Antivirus Agent 100%
• Cellular Immunity 100%
• Passive Immunization 100%
• Hepatitis B Virus 100%
• Chemotherapy 100%
• Hepatitis B 50%
• Acute Lymphoblastic Leukemia 25%
• Allogeneic Hematopoietic Stem Cell Transplantation 25%
• Antiviral Therapy 25%
• Lamivudine 25%
• Hepatitis B Core Antibody 25%
• Hepatitis B Antibody 25%
• Virus Carrier 25%
• Hepatitis B Antigen 25%
• Immunity 25%

Keyphrases

• Allogeneic Blood Stem Cell Transplantation 100%
• Adoptive Immunity Transfer 100%
• Antiviral Chemotherapy 100%
• Hepatitis B Virus 100%
• Acute Lymphoblastic Leukemia 33%
• Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) 33%
• 12-year-olds 33%
• Unrelated Donor 33%
• Young Female 33%
• HLA-identical Sibling 33%
• Lamivudine 33%
• Hepatitis B Surface Antigen (HBsAg) 33%
• Hepatitis B Carrier 33%
• Anti-hepatitis B Surface Antibody 33%
• Hepatitis B Envelope Antigen 33%
• Preemptive Antiviral Therapy 33%
• Anti-hepatitis B Core Antibody 33%
• Hepatitis B Virus Infection 33%

Immunology and Microbiology

• Adoptive Immunity 100%
• Stem Cell Transplantation 100%
• Hepatitis B Virus 100%
• Hepatitis B 50%
• Allogeneic Hematopoietic Stem Cell Transplantation 25%
• Immunity 25%
• Virus Carrier 25%
• Hepatitis B Surface Antibody 25%
• Hepatitis B Core Antibody 25%
• HBsAg 25%
• Hepatitis B Antigen 25%